<DOC>
	<DOC>NCT00002407</DOC>
	<brief_summary>The purpose of this study is to see if it is safe and effective to give one of three different triple-drug combinations to HIV-infected patients who have never been treated with anti-HIV drugs.</brief_summary>
	<brief_title>A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs</brief_title>
	<detailed_description>In this open-label, strategic study patients are evaluated at Weeks 0, 1, 2, 4, 8, 12 to Week 48 after being treated on one of the following regimens: Stavudine (d4T) + Didanosine (ddI) + Lamivudine (3TC) or d4T + ddI + Indinavir or d4T + ddI + Nevirapine.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria Patients must have: Diagnosed asymptomatic HIV infection. HIV1 RNA greater than 500 copies/ml. CD4+ Tcell count greater than 200/mm3. Never received antiretroviral therapy. Exclusion Criteria Coexisting Condition: Excluded: Severe nonHIVrelated disease. Patients with the following prior conditions are excluded: History of neuropathy. Prior Medication: Excluded: Investigational drug within 1 month prior to study. Immunomodulatory drug within 1 month prior to study. Prior Treatment: Excluded: Radiation therapy within past month. Chemotherapy within past month.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1998</verification_date>
</DOC>